About Ischemia Technologies
Ischemia Technologies was a Healthcare company based in Waltham (United States) founded in 1997, and was acquired by Abbott in February 2005. Develops, manufactures, and markets in vitro diagnostic tests for detecting cardiac ischemia. It operates on a B2B model. Ischemia Technologies has raised $12.7 million across 3 funding rounds from investors including Plymouth Growth, Abbott Global Point of Care and Goodman. The company is recorded as dissolved. Its focus areas include Medical Devices, Diagnostic Testing and In Vitro Diagnostics. Its competitors include Infraredx, Ionetix and Cleveland HeartLab; 3 of its 3 listed competitors have raised funding.
Company details
Ischemia Technologies operates with a B2B model, focusing on providing healthcare solutions, developing medical devices, diagnostic testing, and in vitro diagnostics. Develops, manufactures, and markets in vitro diagnostic tests for detecting cardiac ischemia. It emphasizes efficiency, client-focused solutions, and growth, fostering partnerships and innovation in its operations.
- Headquarters Waltham, United States
- Stage Acquired
- SectorsHealthcare
- Website ischemia.com
- Acquired by Abbott (Feb 2005)
- Total Equity Funding$12.7M (USD)
in 3 rounds
- InvestorsPlymouth Growth
& 2 more
- Acquired byAbbott
(Feb 2005)
Funding Insights of Ischemia Technologies
Ischemia Technologies has successfully raised a total of $12.7M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $12.7M
- Total Rounds 3
- First Round $10.2M
(Dec 2000)
- Investors Count 2
All 3 funding rounds of Ischemia Technologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2003 | Series C | – | – | ||
| Jul 2001 | $2.5M | Series C | – | – | |
| Dec 2000 | $10.2M | Series B | – | – | – |
3 investors in total: 3 institutional.
Investors in Ischemia Technologies
Ischemia Technologies has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Plymouth Growth, Abbott Global Point of Care and Goodman.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Growth stage tech & offline focused VC firm funding companies in the US | 2003 | plymouthgp.com | Ann Arbor, United States | |
| goodmankk.com | ||||
Rapid diagnostics products and solutions for point-of-care testing are provided. | 1900 | globalpointofcare.abbott | Waukegan, United States |
Investor details for Ischemia Technologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Ischemia Technologies
4 dated milestones of Ischemia Technologies across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Ischemia Technologies is founded.
- Funding First funding round of $10.2M.
- Funding Latest funding round, Series C,.
- Exit Acquired by Abbott.
Competitors of Ischemia Technologies
Ischemia Technologies has 3 listed competitors in our database, 3 of them funded. They include Infraredx, Ionetix and Cleveland HeartLab.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| infraredx.com | 1998 | Burlington, United States | $99.99M | 59 | Coronary imaging and plaque detection system | |
| ionetix.com | 2009 | San Francisco, United States | $61.08M | Superconducting cyclotrons for PET radioisotopes are developed by Ionetix. | ||
| clevelandheartlab.com | 2008 | Cleveland, United States | $38.85M | Cardiovascular biomarkers are utilized for disease prevention and management. |
Detailed competitors of Ischemia Technologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
3 companies that operate in the same segment as Ischemia Technologies (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ischemia Technologies
Complete news archive for Ischemia Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ischemia Technologies
Ischemia Technologies was founded in 1997 and raised its 1st funding round 3 years after it was founded.
Ischemia Technologies is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Ischemia Technologies is a funded company, having raised a total of $12.7M across 3 funding rounds to date. The company's 1st funding round was a Series B of $10.2M, raised on Dec 2000.
Ischemia Technologies operates with a B2B model, focusing on providing healthcare solutions, developing medical devices, diagnostic testing, and in vitro diagnostics. Develops, manufactures, and markets in vitro diagnostic tests for detecting cardiac ischemia. It emphasizes efficiency, client-focused solutions, and growth, fostering partnerships and innovation in its operations.
Ischemia Technologies's top competitors include Infraredx, Ionetix and Cleveland HeartLab.
Ischemia Technologies has 3 investors. Key investors include Plymouth Growth, Abbott Global Point of Care, and Goodman.
Yes. Ischemia Technologies was acquired by Abbott in February 2005.